|
市場調查報告書
開放性肥胖市場：藥劑開發的新機會和策略
The Wide-Open Obesity Market: New Opportunities and Strategies for Drug Development
|
開放性肥胖市場：藥劑開發的新機會和策略 是由出版商Decision Resources, Inc.在2010年11月所出版的。
這份英文市場調查報告書價格從美金4600起跳。
肥胖和最普遍的共存症2型糖尿病、對人體的健康有很大的威脅、重要性要逐漸的擴大。肥胖市場的尚未被滿足的需求高且有多數商業的潛在性、目前可取得的藥劑都無成功、補貼也尚未完善。新的治療法及朝目標前進的研究開發正積極推動中。
本報告書內容包括:肥胖市場的概要、目前的治療法和課題、新的治療策略和標的、交易和合作趨勢等彙整、內容綱要摘記如下:
實施摘要
肥胖市場的介紹
目前的肥胖治療藥不合期待
- 目前可得手的藥劑
- 安全性問題和產品回收
- 新興的治療法
病因學的經過和新的藥劑標的
- 能源保存和支出路徑
- 瘦體素類似體和瘦體素増感劑
- 二醯甘油酯Acetyltransferase抑制劑
- stearoyl CoA》desaturase-1抑制劑
- 肉鹼・棕櫚醯基轉移酶作動藥
- microsomal triglyceride 轉移蛋白質質抑制劑
- 中樞神經系統仲介食慾・飽食信號
- Monoamine 神經傳達活動增強劑
- 鴉片類受體對抗藥
- melanocortin受體作動藥
- 神經縮氨酸Y受體調節劑
- agutti相關縮氨酸抑制劑
- 黑色素凝集赫爾蒙受體抑制劑
- 胃腸仲介食欲・飽食信號
- Glucagon様縮氨酸
- 蛙皮素類似體
- 神經縮氨酸Y需求體作動藥
- 胃飢素對抗藥
- Amylin作動藥
- 其他藥理額的減量法
- 11β》羥基代氫酵素1型阻礙劑
- 相近蛋白質活性因子
肥胖的創藥和藥劑開發的今後展望
圖表
Abstract
Questions Answered
- Obesity and its most common comorbidity, type 2 diabetes, are a
significant public health threat and an important and growing pharmaceutical
market. How large is the current obesity market? How much will this market
grow over the next ten years? What factors will drive this market growth?
- Despite the high unmet need and the tremendous commercial potential in the
obesity market, none of the currently available drugs have been particularly
successful, and reimbursement has been poor. What factors are limiting the
success of current obesity treatments? What evidence will payers require to
include an obesity drug in their formulary?
- The paucity of currently available agents for treating obesity and the
drawbacks of these agents have drawn the attention of the pharmaceutical
industry and generated a pipeline of novel therapies. Which novel obesity
therapies are poised to launch in the near term? What are the strengths and
weaknesses of each of these agents? How are these drugs vulnerable to emerging
therapies?
- The high level of unmet need in the obesity market is fueling an abundance
of R&D on new approaches and novel targets. Which new treatment strategies
are being pursued, and which are the most advanced? Which novel obesity
targets hold the most promise for drug discovery and development?
- The current market landscape offers innovative biotech companies
significant commercial opportunities. Which biotech companies have
developed innovative approaches to drug discovery and development? How far
have these programs advanced?
- Pharmaceutical companies entering the obesity field can reduce their risk
through strategic partnerships with early-stage innovators. Which
pharmaceutical companies have formed major alliances with biotech companies?
Which therapeutic strategies have drawn the most interest among corporate
partnerships?
Scope
- Introduction to the obesity market: Overview of obesity and its
etiology, market drivers, market size and forecast.
- Current therapies and drawbacks: Mechanisms of action, efficacy,
safety and tolerability, centrally acting and peripherally acting agents.
- Primary data: Data from two surveys conducted by Decision Resources
of U.S. managed care organization (MCO) pharmacy directors, primary care
physicians, and endocrinologists; these primary data describe what payers,
physicians, and patients expect of obesity therapies.
- New treatment strategies: Lorqess, Qnexa, Contrave, mechanisms of
action, combinations of centrally acting agents, combinations of hormone
analogues, novel targets, alternative pathways.
- Novel targets: Mechanisms of action, energy storage and expenditure
pathways, central nervous system (CNS)-mediated appetite and satiety
signaling, centrally acting agents, peripherally acting agents, other
pharmacological approaches for weight loss.
- Dealmaking and partnerships: Partnering activities, innovative
biotech companies, risk reduction, development progress.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction to the Obesity Market
- Current Obesity Therapies Fail to Meet Expectations
- Currently Available Agents
- Safety Concerns and Product Withdrawals
- Emerging Therapies
- Etiological Pathways and Novel Drug Targets
- Energy Storage and Expenditure Pathways
- Leptin Analogues and Leptin Sensitizers
- Diacylglycerol Acetyl Transferase Inhibitors
- Stearoyl CoA Desaturase-1 Inhibitors
- Carnitine Palmitoyltransferase-1 Agonists
- Microsomal Triglyceride Transfer Protein Inhibitors
- CNS-Mediated Appetite and Satiety Signaling
- Potentiators of Monoamine Neurotransmitter Activity
- Opioid Receptor Antagonists
- Melanocortin Receptor Agonists
- Neuropeptide Y Receptor Modulators
- Agouti-Related Peptide Inhibitors
- Melanin-Concentrating Hormone Receptor Inhibitors
- GI-Mediated Appetite and Satiety Signaling
- Glucagon-Like Peptide
- Bombesin Analogues
- Neuropeptide Y Receptor Agonists
- Ghrelin Antagonists
- Amylin Agonists
- Other Pharmacological Approaches for Weight Loss
- 11β Hydroxysteroid Dehydrogenase Type 1 Inhibitors
- Sirtuin Activators
- Outlook for Obesity Drug Discovery and Development
- Bibliography
Tables
- 1. Major Complications and Comorbidities Related to Obesity and Type 2
Diabetes
- 2. Key Obesity Drugs That Have Been Marketed, 1990-2010
- 3. Formulary Tier Status of Obesity Therapies Among Surveyed U.S. Managed
Care Organizations
- 4. Earliest Possible Major-Market Launches for Emerging Obesity Therapies
- 5. Select Candidates in Development for Obesity
- 6. Select Obesity-Related Alliances
Figures
- 1. Average Weight-Loss Effi cacy Expected by Clinicians and Patients from
Novel Obesity Therapies
- 2. Neural and Hormonal Mediators of Hunger and Satiety Signals
- 3. Factors Infl uencing Formulary Decisions for Obesity Drugs Among
Surveyed U.S. Managed Care Organizations
|
